Tango Therapeutics' lead candidate TNG462 has been granted Orphan Drug Designation by the FDA for pancreatic cancer treatment, providing seven years of market exclusivity upon approval.
Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.
Tango Therapeutics' TNG462 demonstrates clinical activity in NSCLC and pancreatic cancer, with a 43% ORR in cholangiocarcinoma, showcasing a favorable safety profile.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.